GLP-1对糖尿病中认知功能的作用和机制
Xiaoke Dou1,2, Lei Zhao3, Jing Li2
1Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, China.
Frontiers in neuroscience
|April 2, 2025
概括
糖尿病 (DM) 会影响认知. 类似葡萄糖-1受体激动剂 (GLP-1RAs) 在保护大脑功能和治疗与DM相关的认知衰退方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 糖尿病是一种与认知障碍相关的代谢障碍.
- 类似葡萄糖-1 (GLP-1) 和其受体 (GLP-1R) 具有神经保护性.
研究的目的:
- 审查DM对认知功能的影响.
- 探索GLP-1受体激动剂 (GLP-1RAs) 的神经保护机制.
主要方法:
- 对DM,认知障碍和GLP-1信号研究的文献综述.
- 对糖尿病相关认知障碍阶段的分析.
- 检查GLP-1RAs多方面的功能.
主要成果:
- 与糖尿病相关的认知障碍通过几个阶段进展:下降,轻度认知障碍 (MCI) 和痴呆症.
- GLP-1RAs显示神经保护,抗感染和代谢调节.
- GLP-1RAs显示出改善DM患者认知功能的潜力.
结论:
- GLP-1RAs在DM的认知功能障碍中具有有前途的治疗应用.
- GLP-1RA神经保护的相互连接机制需要进一步研究.
- 了解这些机制,可以为糖尿病相关的认知功能障碍提供有针对性的治疗.
相关概念视频
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
143
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
143


